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Abstract
Background: Published false positive research findings are a major problem in the process of
scientific discovery. There is a high rate of lack of replication of results in clinical research in general,
multiple sclerosis research being no exception. Our aim was to develop and implement a policy
that reduces the probability of publishing false positive research findings.
We have assessed the utility to work with a pre-publication validation policy after several years of
research in the context of a large multiple sclerosis database.
Methods: The large database of the Sylvia Lawry Centre for Multiple Sclerosis Research was split
in two parts: one for hypothesis generation and a validation part for confirmation of selected
results. We present case studies from 5 finalized projects that have used the validation policy and
results from a simulation study.
Results: In one project, the "relapse and disability" project as described in section II (example 3),
findings could not be confirmed in the validation part of the database. The simulation study showed
that the percentage of false positive findings can exceed 20% depending on variable selection.
Conclusion: We conclude that the validation policy has prevented the publication of at least one
research finding that could not be validated in an independent data set (and probably would have
been a "true" false-positive finding) over the past three years, and has led to improved data analysis,
statistical programming, and selection of hypotheses. The advantages outweigh the lost statistical
power inherent in the process.
Background
The validity of published research findings is receiving
appropriate scrutiny [1-4]. Erroneous conclusions are
commonplace [1-4]. Analyses performed on datasets prior
Published: 10 April 2008
BMC Medical Research Methodology 2008, 8:18 doi:10.1186/1471-2288-8-18
Received: 18 December 2007
Accepted: 10 April 2008
This article is available from: http://www.biomedcentral.com/1471-2288/8/18
© 2008 Daumer et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Research Methodology 2008, 8:18 http://www.biomedcentral.com/1471-2288/8/18
Page 2 of 7
(page number not for citation purposes)
to focus on specific hypotheses or models do hazard the
generation of hypotheses filtered through unwitting bias.
Hypothesis-generating experiments are necessary but
multiple model selection may not be capable of identify-
ing valid conclusions. Pre-publication validation aims to
reduce the number of false positive findings.
Multiple sclerosis is a disease of the nervous system with
highly variable outcomes. Relapses are characteristic and
average 0.5/year [5] in the relapsing phase. Half of
patients need aid for walking or are worse after 15 years
[6]. In clinical trials annualized relapse rates and disease
progression (as measured by the Expanded Disability Sta-
tus Scale or EDSS) have been used as endpoints. Magnetic
resonance imaging (MRI) of the brain detects inflamma-
tory activity and change in brain volume. MRI-related
endpoints include new gadolinium-enhancing lesions
and total brain lesion volume (T2 weighted image) but
remain unvalidated surrogates for long-term outcome.
Several medications reduce relapse rate and/or MRI
lesions but are uncertain suppressors of disease progres-
sion. The Sylvia Lawry Centre for MS Research (SLC) was
developed to improve outcome-based trial research in MS.
We describe the background of the SLC, its framework for
statistical validation and studies demonstrating the Cen-
tre's policies.
The validation policy of the Sylvia Lawry Centre for MS 
Research
The validation policy of the SLCMSR prescribes a random
split into two parts for hypothesis generation and valida-
tion, a variant of independent replication by split sample
validation.
Training and validation parts contain 40% and 50% of the
data respectively. When new databases are added, the
remaining 10% of data is used for mixing purposes. The
training part is available to researchers/statisticians for
exploration and investigation and important findings are
selected for validation. Approved proposals go to the
"data-trustee", who evaluates the validation dataset, and
summarizes the result for the publication/validation com-
mittee, the analyst and collaborative researchers. Results
obtained from the training part of the database, annotated
by confirmation information are published (see Addi-
tional file 1, resp. Lit. [7]).
Proactive application of this process applied to SLC
projects coming to the final validation step is described
[8-11]. A common goal in chronic diseases is to find pre-
dictors of an outcome variable of interest among larger
sets of potential explanatory variables. These variables can
be continuous, binary or count variables and lead in turn
to linear, logistic, or Poisson regression models. After
identification of significant predictors in the training por-
tion of the database in a multiple regression model, we
attempted to confirm these in the validation part of the
database. By "successful validation" we meant that the
same predictors remained significant on a 5% level in a
multiple regression model in the closed part (see, e.g., Alt-
man).
A simulation study assessed the influence of variable
selection on the overall significance level. In practice, the
distribution of key variables and number of patients in the
specific subgroups are determined within the validation
step to ensure correspondence of the datasets.
Methods
a) Case studies and examples
Example 1
Relevant to the use of T2 lesion volume as a surrogate
marker for disability, we investigated the relationship
between this MRI outcome variable, and a set of continu-
ous, ordinal and binary clinical determinants as potential
explanatory variables. Unexpectedly, a non-linear pla-
teauing relationship between the ordinal predictor
Expanded Disability Status Scale (EDSS), and the MRI
outcome for a set of 1312 placebo patients with MS from
randomized clinical trials was found (Fig. 1, see [8] for
details on the variables and results of this project).
We validated this finding in steps, the key step being
whether the EDSS predictor led to improvement (p <
0.05) of model fit when entered in a nonlinear (as com-
pared to linear) fashion. We then calculated Spearman's
correlation coefficient over the range of EDSS values and
considered the validation of the plateauing relationship
successful, if the overall correlation with EDSS was posi-
tive and significant (p < 0.05), and if the correlation coef-
ficient for EDSS >4 was not significantly different from
zero, (95% confidence interval included zero). The size of
the validation sample corresponding to this project con-
tained 848 patients. The distributions with respect to the
key variables were similar in training and validation sets,
indicating comparability and suitability for validation. All
predictors assessed were validated in the multiple regres-
sion fits. The major finding of a plateauing relationship
between EDSS and transformed T2 lesion burden was
unequivocally confirmed – T2 lesion volume does not
seem to be a good surrogate for disability in MS patients.
Example 2
The development of gadolinium enhancing lesions is
often used in phase II clinical MS trials to evaluate the
potential efficacy of new drugs. The presence of these
lesions is interpreted as an indicator of acute disease activ-
ity in MS patients [9]. Predictors of enhancement statusBMC Medical Research Methodology 2008, 8:18 http://www.biomedcentral.com/1471-2288/8/18
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could be useful for the selection of patients for MRI mon-
itored trials.
In a multiple regression model with clinical and demo-
graphic predictors ("disease course", "age at disease
onset" and "disease duration" [9], the MRI predictor T2
lesion burden significantly improved the prediction of
enhancement status in the open part of the SLC database.
We then defined the validation to be successful if the val-
ues of several statistics in the closed part of the database,
most importantly the positive predictive value, are above
the lower endpoints of approximate one-sided 95% pre-
diction (99% for "excellent" validation) intervals for the
anticipated value in the validation part of the database.
We found that the increase in positive predictive value
over the a priori chance of enhancement in the closed
database when T2 lesion burden was included as predictor
exceeded the prespecified level defining "excellent" vali-
dation.
Example 3
We investigated within trials whether relapses contribute
to the development of subsequent sustained increase of
impairment and disability in patients with MS as meas-
ured by the EDSS [10]. On-study relapse data was col-
lected in so-called "sacrifice" periods of 80, 120, 160, or
200 days. Confirmed increase in EDSS was defined as at
least one point rise confirmed by another visit at least 135
days later. In two comparison groups with two different
cut-point splits: a) 0 versus at least 1 relapse during the
sacrifice period, and b) 0 or 1 relapse versus at least 2
relapses during the sacrifice period, analysis was based on
a two-sided log rank test to determine whether time to
confirmed rise in EDSS is the same for two groups. Results
are displayed in terms of hazard ratio and 95% confidence
interval. There were 256 relapsing remitting MS patients
in the training database for this analysis. Combining the
four different sacrifice periods, and the two different cut-
point splits results in eight tests. The test with the smallest
p-value was the one for 120 days sacrifice period and cut-
point split 0 versus at least 1 relapse during sacrifice
period (likelihood ratio test p-value was 0.0012, esti-
mated hazard ratio = 2.26, 95% confidence interval [1.36;
3.75]). Such a result if validated – would support the
assumption that reduction of relapses slows down the
accumulation of disability.
In the 320 patients available in the validation sample
comparable to the training sample for distribution of the
key variables (p-value of the one-sided Wald test was
0.109) findings could not be validated. We concluded
that "there is no consistent effect of on-study relapses on
Plateauing relationship between EDSS and T2 lesion volume in the open part of the SLC database [8] Figure 1
Plateauing relationship between EDSS and T2 lesion volume in the open part of the SLC database [8].BMC Medical Research Methodology 2008, 8:18 http://www.biomedcentral.com/1471-2288/8/18
Page 4 of 7
(page number not for citation purposes)
the subsequent development of sustained EDSS score
increase during a typical clinical study observation
period".
b) Simulation studies and validation cost
In simulation studies to determine the effect of variable
selection on the significance level of global F-tests in mul-
tiple regression analysis (data not shown), observed error
rates were found to exceed 20% for both forward and
backward selection. With only one or two variables in the
model, forward selection has more flexibility to identify
"significant" predictors, leading to more false positive
findings than backward selection. Forward selection and
backward selection produce comparable error rates with 3
or more variables. With six predictors in the regression
model, forward selection maintains the significance level
of 5%.
To assess the "cost" of splitting the database we used a
one-sided, one-sample Gauss-test situation with 900
observations, (400 would be available in the training
database, and 500 for confirmation; see Figure 2).
Results
Since the SLCMSR validation policy was put in place, ten
larger scientific projects have been finalized using the
training portion of the database. In five of them, the find-
ings of the training data were selected for confirmation in
the validation part of the database. In four of these, train-
ing dataset findings were replicated in the validation data-
Displays the power for four different validation scenarios plotted against shift in percent of standard deviation: the first for the  complete dataset on a 5% significance level; the second for testing on the validation stage only (N = 500 patients) on 5% signif- icance level; the third for testing on the training set (N = 400 patients) with 10% and on the validation set (N = 500) with 5%;  and the fourth scenario for testing on a 5% significance level in the training data (N = 400 patients) and in the validation data (N  = 500 patients) Figure 2
Displays the power for four different validation scenarios plotted against shift in percent of standard deviation: the first for the 
complete dataset on a 5% significance level; the second for testing on the validation stage only (N = 500 patients) on 5% signif-
icance level; the third for testing on the training set (N = 400 patients) with 10% and on the validation set (N = 500) with 5%; 
and the fourth scenario for testing on a 5% significance level in the training data (N = 400 patients) and in the validation data (N 
= 500 patients). There is a sacrifice in power using this validation scheme.BMC Medical Research Methodology 2008, 8:18 http://www.biomedcentral.com/1471-2288/8/18
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set. In one, the "relapse and disability" project as
described in section II (example 3), findings could not be
confirmed in the closed portion of the database – without
the validation policy this would have lead to publication
of a false-positive finding. The other five projects were
finalized without result validation. In each case the
authors, committee members and journal reviewers
agreed that the findings obtained in the training set were
sufficient for answering the question at hand. In some
cases the hypothesis had clearly been formulated before
touching the training set. In another example only a rough
estimate of the upper bound of the mortality rate was pro-
posed to decide about the feasibility of a trial design
[12,13].
Discussion
Exploratory data analysis typically starts with data descrip-
tion entailing comparisons, and often generating statisti-
cal hypotheses. Ideally, however, all hypotheses should be
formulated prior to descriptive analysis (or even before
data collection). In practice data description leads to new
questions, to investigation of new relationships by formu-
lating hypotheses, and then formal testing. Descriptive
statistical analyses can substantially endanger the validity
of formal statistical inference by destroying the probabil-
istic basis of inferential statistics.
Substantial statistical methodology has been dedicated to
overcoming this problem including replication, cross-val-
idation, limits for family-wise error rates and Bonferroni-
adjustment for multiple testing [14,15]. These methods
could be applied to control the overall significance level
for a type I error, but it is usually impossible to quantitate
prior "data dredging" [15-19].
Significance levels can be controlled by dividing the data
set into separate parts prior to data analysis. Hastie et al.
[16], for example, recommend randomly splitting the
database into 1) a training set, 2) a validation set, and 3)
a test set to evaluate the predictive accuracy of the model.
Van Houwelingen and le Cessie [20] suggest using one
part of the database to select the covariates, a second to
estimate the regression coefficients, and a third to assess
the prediction rule.
The SLCMSR hosts a large database on multiple sclerosis
patients from clinical trials and natural history studies.
Data donors do not influence the publication process,
and SLCMSR follows strict rules guaranteeing non-identi-
fiability of individual data sets. Anonymization and split-
ting of the trials make it impossible for SLCMSR and
collaborative researchers to identify patients and trials
with individual data donors.
Splitting the large SLC database into two parts yields one
training part for hypothesis generation, and a second for
validation purposes. Only large databases are suitable for
splitting, because in secondary analyses patient numbers
drop considerably. The validation part of the database is
reserved for confirmation of single pre-specified hypothe-
ses. The major finding of one otherwise finalized project
could not be validated, and the publication of a false-pos-
itive finding was prevented. More recent findings [21] sug-
gest that even a consistent effect of on-study relapses on
subsequent "sustained progression" could not be inter-
preted as evidence for a link between relapse frequency
and the accumulation of true, unremitting disability.
However, one should be aware that it can of course not be
excluded that in some cases the application of the valida-
tion policy will lead to the publication of false negative
findings. This disadvantage is related to the inherent loss
of power induced by the split of the data base. Therefore,
we think that our procedure is particularly useful in areas
where the presence of false-positive findings and a consid-
erable degree of "optimism" is common. This is certainly
true in MS research, but may be frequent in other areas of
clinical research as well.
Moreover, we believe that in general having this valida-
tion policy leads to a more sensible and thorough data
analysis, programming and code checking, and selection
of hypotheses to validate.
Simulations of the true significance level under the null
hypothesis of global F-tests after forward and backward
variable selection showed (N = 746) that the significance
level can easily go beyond 20% when only a small
number of predictor variables are included in the model.
The price to pay for splitting the database is a reduction in
statistical power. We simulated power levels similar to a
typical study at the SLC, and we demonstrated that the
shift in percent of standard deviation for a one-sided
Gauss-test detected with 80% power needs to be nearly
double the size with result validation than without result
validation. In other words, statistically significant findings
need to be detected twice: in the training sample and in
the validation sample. However, the price of publishing
false positive research findings in a field with many false
dawns justifies validation efforts.
Is the proposed method of result validation generally suit-
able for research questions or databases? We think that
properly designed randomized controlled clinical trials
do not necessarily need result validation – although com-
pletely separate and independent replications should not
be discouraged. Even when additional hypotheses are to
be tested at the end of the trial, Bonferroni adjustmentsBMC Medical Research Methodology 2008, 8:18 http://www.biomedcentral.com/1471-2288/8/18
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can be sufficient to control the significance level. Epidemi-
ological studies, however, are not scientific experiments,
and, the study design is less structured than in clinical tri-
als, and often lacking randomization.
In addition false-positive findings from large-scale studies
cannot be disproved since other studies are typically
smaller and do not have the power to do so. When a large
group of researchers works on a scientific field using the
same database, result validation is a powerful way to
reduce the probability of publishing false positive find-
ings.
Allision [22] states that there is an ongoing debate
whether studies with microarrays require any validation
guidelines that are fundamentally different from other
types of study [23,24].
We think that different ways to construct the open and
closed part of the data base – e.g. selecting randomly indi-
vidual data packages (or random fractions thereof) to go
either in the open or in the closed part – may be interest-
ing modifications of our policy. Future work will aim to
define the exact goals of such extended validation studies
and at an assessment of which validation procedures will
meet those goals.
Ioannidis [1] states that there is no "gold-standard" for
validation in general, but that the percentage of published
false positive findings can be reduced by better-powered
studies, i.e. large-scale studies, low-bias meta-analyses,
registration of studies and networking of data collections
– similar to randomized controlled trials, and a split-team
approach.
Conclusion
We conclude that the validation policy has prevented the
publication of at least one research finding that could not
be validated in an independent data set (and probably
would have been a "true" false-positive finding) over the
past three years, and has led to improved data analysis,
statistical programming, and selection of hypotheses. The
advantages outweigh the lost statistical power inherent in
the process.
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